Will a massive government deal be the cure for Pfizer's (PFE) sluggish stock performance? The pharmaceutical giant just pulled a strategic masterstroke, insulating itself from a crippling new industry headwind with a landmark $70 billion domestic investment. But while options traders are screaming "bullish," the underlying fundamentals show a complicated story with an alarming revenue problem. Join D-Risk as we dissect this trade, weigh the game-changing political maneuver against the cautious analyst ratings, and use technicals to find the critical price levels that will determine if this stock is due for a powerful breakout or a false alarm.
